Potential anti-atherosclerotic effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus topical collection on macrovascular complications in diabetes

Current Diabetes Reports

Volumn 14, Issue 2, 2014, Pages

  Dhindsa, Sandeep ^a   Jialal, Ishwarlal ^b,c  

^a TEXAS TECH UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antioxidant; Atherosclerosis; CD26; CRP; Diabetes; Dipeptidyl peptidase 4; DPP 4; Endothelial function; Inflammation; Lipids; Postprandial hyperlipidemia; T2DM

Indexed keywords

3 NITROTYROSINE; CHEMOKINE RECEPTOR CCR2; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; I KAPPA B KINASE BETA; INCRETIN; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; INTERMEDIATE DENSITY LIPOPROTEIN; METFORMIN; PLACEBO; SITAGLIPTIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN; VILDAGLIPTIN;

ANTIATHEROSCLEROTIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG ACTIVITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; MEAN AMPLITUDE GLYCEMIC EXCURSION; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; THROMBOCYTE FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84895077518     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0463-z     Document Type: Article

References (49)

1. Seshasai SR, Kaptoge S, Thompson A, et al. Emerging risk factors collaboration: diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829-41.
2. Wing RR, Bolin P, Brancati FL, et al. Look AHEAD Research Group: cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145-54.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.
4. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study (prospective pioglitazone clinical trial in macrovascular events): a randomized controlled trial. Lancet. 2005;366:1279-89.
5. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. BMJ. 2011; (PMID: 22115901).
6. Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diabetes Vasc Dis Res. 2012;9:109-16.
7. Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metabol. 2013;15:112-20.
8. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27 Suppl 3:57-64.
9. Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol. 2013;10:73-84.
10. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011;124(1 Suppl):S3-S18.
11. Muscelli E, Casolaro A, Gastaldelli A, et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab. 2012;97:2818-26.
12. Marfella R, Barbieri M, Grella R, et al. Effects of vildagliptin twice daily vs sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complicat. 2010;24:79-83.
13. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012;35:2076-82.
14. Barbieri M, Rizzo MR, Marfella R, et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis. 2013;227:349-54. Interesting preliminary study showing benefit of Vildagliptin and Sitagliptin on sub-clinical atherosclerosis as evidenced by a decrease in carotid IMT.
15. Di Flaviani A, Picconi F, Di Stefano P, et al. Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. Diabetes Care. 2011;34:1605-9.
16. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681-7.
17. Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol. 2009;53:S35-42.
18. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287:E1209-15.
19. Irace C, DeLuca S, Shehaj E, et al. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diabetes Vasc Dis Res. 2012;10:72-7.
20. van Poppel PCM, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011;34:2072-7. First report showing a significant improvement in flow mediated dilation with Vildagliptin therapy compared with acarbose.
21. Kubota Y, Miyamoto M, Takagi G, et al. The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin improves vascular endothelial function in Type 2 Diabetes. J Korean Med Sci. 2012;27:1364-70.
22. Matsubara J, Sugiyama S, Akiyama E, et al. Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013;77:1337-44.
23. Hein TW, Singh I, Vasquez-Vivar J, et al. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis. 2009;206:61-8.
24. Devaraj S, Jialal I. Dysfunctional endothelial progenitor cells in metabolic syndrome. Exp Diabetes Res. 2012; (PMID: 21941528).
25. Fadini GP, Boscaro E, Albiero M, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes. Diabetes Care. 2010;33:1607-9.
26. Jialal I, Bajaj M. Commentary: DPP-4 inhibitors and atherosclerosis: the promise. Atherosclerosis. 2013;227:224-5.
27. Devaraj S, Dasu MR, Jialal I. Diabetes is a proinflammatory state: a translational perspective. Expert Rev Endocrinol Metab. 2010;5:19-28.
28. Makdissi A, Ghanim H, Vora M, et al. Sitagliptin exerts an anti-inflammatory action. J Clin Endocrinol Metab. 2012;97:3333-41. First comprehensive report on the anti-inflammatory effects of Sitagliptin. Acute (<6 hours) as well as chronic effects (12 weeks) were studied.
29. Chaudhuri A, Ghanim H, Vora M, et al. Exenatide exerts a potent anti-inflammatory effect. J Clin Endocrinol Metab. 2012;97:198-207.
30. Jialal I, Devaraj S. Circulating vs cellular biomarkers of inflammation in type 1 diabetes: the superiority of C-reactive protein. Cytokine. 2012;60:318-20.
31. Satoh-Asahara N, Sasaki Y, Wada H, et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism. 2013;62:347-51.
32. Derosa G, Maffioli P, Ferrari I, et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res. 2010;42:663-9.
33. Derosa G, Maffoli P, Salvadeo SAT, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism. 2010;59:887-95.
34. Ansar S, Koska J, Reaven PD. Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc Diabetol. 2011; (PMID: 21736746).
35. Pang J, Chan DC, Barrett PH, Watts GF. Postprandial dyslipidemia and diabetes: mechanistic and therapeutic aspects. Curr Opin Lipidol. 2012;23:303-9.
36. Farr S, Adeli K. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states. Curr Opin Lipidol. 2012;23:56-61.
37. Matikainen N, Manttari S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 2006;49:2049-57.
38. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:366-73. Study convincingly showing benefit of Sitagliptin therapy on postprandial hyperlipidemia.
39. Eliasson B, Möller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomized double-blind placebo-controlled study. Diabetologia. 2012;55:915-25.
40. Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48:592-8.
41. Gupta AK, Verma AK, Kailashiya J, et al. Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. Platelets. 2012;23:565-70.
42. Post S, van den Broek AJ, Rensing BJ, et al. Reduced CD26 expression is associated with improved cardiac function after acute myocardial infarction: insights from REPERATOR study. J Mol Cell Cardiol. 2012;53:899-905.
43. Theiss HD, Brenner C, Engelmann MG, et al. Safety and efficacy of sitagliptin plus granulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) - rationale, design and fist interim analysis. Int J Cardiol. 2010;145:282-4.
44. Jialal I, Devaraj S, Venugopal SK. Oxidative stress, inflammation, and diabetic vasculopathies: the role of alpha tocopherol therapy. Free Radic Res. 2002;36:1331-6.
45. Koren S, Shemesh-Bar L, Tirosh A, et al. The effect of sitagliptin vs glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther. 2012;14:561-7.
46. Tardiff JC, Lesage F, Harel F, Romeo P, Pressacco J. Advances in cardiovascular imaging: imagining biomarkers in atherosclerosis trials. Circ Cardiovasc Imaging. 2011;4:319-33.
47. Read PA, Khan FZ, Heck PM, et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3:195-201.
48. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33:187-215.
49. Scheen AJ. Cardiovascular effects of Dipeptidyl Peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med. 2013;125:7-20.